2023 U.S.-Booked Air Volume: $67.2 million
Consolidated U.S. TMC: BCD 

Biopharmaceutical company Abbvie’s 2023 U.S.-booked air travel increased slightly, according to a BTN estimate.

AbbVie’s 2023 net revenue fell 6 percent year over year to $54 billion after the company lost exclusivity in the U.S. for antirheumatic drug Humira. However, AbbVie expects to return to “modest” growth in 2024 and “robust” growth in 2025 after expanding its other activities and buying two companies headquartered in Massachusetts. In February 2024, AbbVie completed the acquisition of Waltham-based oncology biotech company ImmunoGen for $10.1 billion. That was followed in August with completion of the acquisition of Cambridge-based neuroscience specialist Cerevel Therapeutics for $8.7 billion.

As of the end of 2023, AbbVie had around 50,000 employees, unchanged from the year before.